- Home
- OCEA
as 01-17-2025 4:00pm EST
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 20.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 617.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.46 - $7.79 | Next Earning Date: | 01-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Ocean Biomedical Inc. News
OCEA Breaking Stock News: Dive into OCEA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
GlobeNewswire
3 months ago
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
GlobeNewswire
4 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
GlobeNewswire
5 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms
GlobeNewswire
5 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
GlobeNewswire
7 months ago
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
MT Newswires
8 months ago
Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down
GlobeNewswire
8 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Compare OCEA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCEA Ocean Biomedical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.